IGF-1 LR3

Also known as: Long R3 IGF-1, Insulin-like Growth Factor-1 Long Arg3

Muscle & Recovery

Preclinical

IGF-1 LR3 is a potent synthetic analog of insulin-like growth factor-1 engineered to have significantly reduced affinity for IGF-binding proteins, resulting in a half-life of approximately 20–30 hours compared to just minutes for native IGF-1. It acts directly on muscle, bone, and other tissues to promote growth and repair.

Regulatory & Approval Status

Not FDA Approved

IGF-1 LR3 is classified as a research chemical with no FDA approval for any indication; it is distinct from the FDA-approved drug mecasermin.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.